" class="no-js "lang="en-US"> Søren Tulstrup - Medtech Alert
Friday, March 29, 2024
Søren Tulstrup

Søren Tulstrup

About Søren Tulstrup

Soren Tulstrup is President & CEO of Hansa Biopharma AB, an innovative and rapidly growing biopharmaceutical company listed on Nasdaq Nordic. He also serves as board advisor to a number of private and public life science companies in Europe and North America.

Soren Tulstrup has more than 30 years of senior level experience within the global life science industry as CEO/General Manager/Global Franchise Head/Region Head and board director at leading and fast growing companies in Europe, the US and within Emerging Markets.

As CEO of Swiss specialty pharma company Vifor Pharma, Soren Tulstrup initiated and led a major turn-around effort that resulted in significant acceleration of sales growth and a substantial operating margin improvement and led to the separation of Vifor Pharma from the mother group Galenica. Sales grew from CHF 667 million in 2013 to CHF 1.17 billion in 2016 while the operating margin experienced a double-digit percentage point improvement. Driven by the performance of Vifor Pharma, Galenica in 2015 became the best performing share (+98 %) within the Swiss Performance Index, increasing the company’s market cap by approx. CHF 5 billion. Based on this performance and a range of other objective criteria, Soren Tulstrup made the #2 spot on local newspaper Handelzeitung’s list of Switzerland’s most value-adding CEOs in the category Large Companies.

Previously, as CEO of successful biotech company Santaris Pharma, Soren Tulstrup initiated a refocusing of the company’s drug development efforts, established US operations in San Diego, and led business development efforts that resulted in 4 major partner deals within 3 years with a total deal value of almost USD 2 billion in upfront and potential milestone payments, enabling the company to take 3 new drug candidates into clinical development without raising new capital. Santaris Pharma was listed as a Fierce 15 Biotech Company, won the Red Herring Award and was nominated for the SCRIP Award in the category Best Biotech Company before eventually being acquired by Roche for USD 450 million and providing the investors with an attractive return.

Soren Tulstrup holds an MSc. in Economics and Business Administration from Copenhagen Business School and Kellogg Graduate School of Management, Northwestern University. He is also a graduate of the Royal Danish Army Combat School and has served as an armored infantry officer in the Royal Danish Army.

Related Story

Hansa Biopharma Announces Reimbursement in Italy for Idefirix as Desensitization Treatment for Highly Sensitized Patients in Kidney Transplantation

December 8 2022

Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, has announced that the […]

The Scottish Medicines Consortium (SMC) Recommends Use of Hansa Biopharma’s Idefirix® (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

September 13 2022

Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, […]

Hansa Biopharma and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix® in Highly Sensitized Kidney Transplant Patients

August 23 2022

Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological […]

NICE Recommends Use of Hansa Biopharma's Idefirix® (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

June 16 2022

Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, today […]